Clearmind Medicine Appoints Mary-Elizabeth Gifford as Chief of Global Impact to Advance US Partnerships and Governmental Engagement
Clearmind Medicine (Nasdaq: CMND) appointed Mary-Elizabeth Gifford as Chief of Global Impact effective Oct 27, 2025 to lead US partnerships, governmental and regulatory engagement, and strategic alliances in Washington, D.C. and New York.
Gifford previously held the same role at Psyence BioMed and led public policy at the Center for Mind-Body Medicine. The company noted its 31 granted patents, ongoing clinical trials at Yale, Johns Hopkins and Hadassah, and a Scientific Advisory Board with faculty from Harvard, Yale, and Penn.
Clearmind Medicine (Nasdaq: CMND) ha nominato Mary-Elizabeth Gifford come Chief of Global Impact con effetto dal 27 ottobre 2025 per guidare le collaborazioni negli Stati Uniti, l'impegno governativo e regolatorio, e le alleanze strategiche a Washington, DC e New York.
Gifford ha ricoperto in precedenza lo stesso ruolo presso Psyence BioMed e ha guidato la politica pubblica presso il Center for Mind-Body Medicine. L'azienda ha indicato 31 brevetti concessi, trial clinici in corso presso Yale, Johns Hopkins e Hadassah, e un Scientific Advisory Board con docenti di Harvard, Yale e Penn.
Clearmind Medicine (Nasdaq: CMND) designó a Mary-Elizabeth Gifford como Jefa de Impacto Global con efecto a partir del 27 de octubre de 2025 para liderar asociaciones en EE. UU., compromiso gubernamental y regulatorio, y alianzas estratégicas en Washington, D.C. y Nueva York.
Gifford ocupaba previamente el mismo puesto en Psyence BioMed y dirigió la política pública en el Center for Mind-Body Medicine. La empresa señaló sus 31 patentes concedidas, ensayos clínicos en curso en Yale, Johns Hopkins y Hadassah, y un Consejo Científico Asesor con docentes de Harvard, Yale y Penn.
Clearmind Medicine (Nasdaq: CMND)가 2025년 10월 27일부로 Mary-Elizabeth Gifford를 글로벌 임팩트 책임자로 임명하여 미국 파트너십, 정부 및 규제 참여, 그리고 워싱턴 D.C. 및 뉴욕의 전략적 제휴를 이끌게 합니다.
Gifford는 이전에 Psyence BioMed에서 동일한 직책을 맡았고 Center for Mind-Body Medicine에서 공공 정책을 주도했습니다. 회사는 31건의 허가된 특허, 예일대, 존스 홉스대, Hadassah에서 진행 중인 임상을 언급했고, 하버드, 예일, 펜의 교수진으로 구성된 과학자 자문위원회가 있습니다.
Clearmind Medicine (Nasdaq: CMND) a nommé Mary-Elizabeth Gifford au poste de Chef de l'Impact Global à compter du 27 octobre 2025 pour diriger les partenariats américains, l'engagement gouvernemental et réglementaire, et les alliances stratégiques à Washington, D.C. et à New York.
Gifford a occupé auparavant le même poste chez Psyence BioMed et a dirigé les politiques publiques au Center for Mind-Body Medicine. L'entreprise a souligné ses 31 brevets accordés, des essais cliniques en cours à Yale, Johns Hopkins et Hadassah, et un comité consultatif scientifique composé de professeurs de Harvard, Yale et Penn.
Clearmind Medicine (Nasdaq: CMND) hat Mary-Elizabeth Gifford zum Chief of Global Impact ernannt, mit Wirkung ab dem 27. Oktober 2025, um US-Partnerschaften, Regierungs- und Regulierungsengagement sowie strategische Allianzen in Washington, D.C. und New York zu leiten.
Gifford hatte zuvor dieselbe Rolle bei Psyence BioMed inne und leitete die öffentliche Politik am Center for Mind-Body Medicine. Das Unternehmen wies auf 31 erteilte Patente, laufende klinische Studien an Yale, Johns Hopkins und Hadassah hin und ein Scientific Advisory Board mit Fakultätsmitgliedern von Harvard, Yale und Penn.
Clearmind Medicine (Nasdaq: CMND) عيّنت Mary-Elizabeth Gifford رئيسة التأثير العالمي اعتباراً من 27 أكتوبر 2025 لقيادة الشراكات الأمريكية، والمشاركة الحكومية والتنظيمية، والتحالفات الاستراتيجية في واشنطن العاصمة ونيويورك.
شغلت غيفورد سابقاً نفس المنصب في Psyence BioMed وقادت السياسة العامة في Center for Mind-Body Medicine. أشارت الشركة إلى 31 براءة اختراع ممنوحة، وتجارب سريرية جارية في Yale، Johns Hopkins وHadassah، وهناك مجلس استشاري علمي يضم أعضاء هيئة تدريس من Harvard, Yale وPenn.
Clearmind Medicine (Nasdaq: CMND) 任命 Mary-Elizabeth Gifford 为 全球影响力主管，自2025年10月27日起生效，负责领导美国合作伙伴关系、政府与监管参与，以及在华盛顿特区和纽约的战略联盟。
Gifford 之前在 Psyence BioMed 担任同一职位，并在 Center for Mind-Body Medicine 领导公共政策。公司指出其 31 项已授予专利、在耶鲁大学、约翰斯·霍普金斯大学和 Hadassah 的进行中的临床试验，以及由哈佛、耶鲁和宾夕法尼亚大学教授组成的科学顾问委员会。
- None.
- None.
Vancouver, Canada, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel neuroplastogens-derived therapeutics to solve major under-treated health problems, today announced the appointment of Mary-Elizabeth Gifford as Chief of Global Impact. In this role, Gifford will lead efforts to strengthen Clearmind's US partnerships, governmental and regulatory advocacy, and strategic alliances in Washington, D.C. and New York, bridging research, regulation, and patient care to accelerate the advancement of innovative psychedelic medicines.
Prior to joining Clearmind, Gifford served as Chief of Global Impact at Psyence BioMed, a Nasdaq-listed biopharmaceutical company focused on nature-derived psychedelic medicine. She joined Psyence in 2020 from the Center for Mind-Body Medicine, a Washington, D.C.-based non-profit, where she led public policy.
“We are thrilled to welcome Mary-Elizabeth Gifford to Clearmind Medicine,” said Dr. Adi Zuloff-Shani, PhD, CEO of Clearmind Medicine. “Her unparalleled expertise in psychedelic policies and regulatory landscapes, and longstanding collaborations with leading government officials, policy makers and investors oriented to this space, will be instrumental in advancing our US partnerships and positioning Clearmind as a leader in ethical, patient-centered psychedelic therapeutics.”
Gifford, commented, “It’s an honor to join Clearmind Medicine, a psychedelic biopharma distinguished by its IP portfolio of 31 granted patents. With clinical trials underway at both Yale School of Medicine and Johns Hopkins University School of Medicine as well as Hadassah University Medical Center in Jerusalem, and its Scientific Advisory Board that includes faculty physicians from Harvard, Yale, and the University of Pennsylvania, Clearmind aims to set the industry standard for scientific rigor and integrity.” She continued, “I bring deep appreciation for the innovative Clearmind leadership team and for CEO Dr. Zuloff-Shani, whose entrepreneurial achievements at the intersection of medicine, commerce, and science to alleviate human suffering is inspiring.”
Gifford serves pro bono as chair of the non-profit Global Wellness Institute’s Psychedelics & Healing Initiative, whose honorary chair is Rick Doblin, founder of MAPS, the Multidisciplinary Association for Psychedelic Studies. A trusted voice for mental health and psychedelic medicine on Capitol Hill and elsewhere, she was named a “Psychedelic Titan,” one of “the psychedelic industry’s most influential and impactful individuals,” by the news site Microdose. Spirituality & Health Magazine describes Gifford as “the most quietly influential woman working in psychedelics today.”
In May of 2025, Gifford chaired the steering committee for the inaugural Federal Psychedelic Summit, held at the National Press Club in Washington. She addressed the topic of psychedelic business ethics and “Profit with Purpose” at Psychedelic Science 2025 in Denver. She is active with the Johns Hopkins Psychedelic Ethics group and is a member of the Institute of Medical Ethics. In July of 2025, Mary-Elizabeth became the sole biopharma executive selected to study alongside leading attorneys, physicians, researchers and government officials at Harvard Law School ‘s psychedelic policy and law immersion program. A graduate of Brown University, she also had a post-graduate year studying the History of Mind-Body Medicine at Harvard.
About Clearmind Medicine Inc.
Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY0.”
For further information visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
Telephone: (604) 260-1566
US: CMND@crescendo-ir.com
General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses it discusses accelerating the advancement of innovative psychedelic medicines, advancing its US partnerships and positioning Clearmind as a leader in ethical, patient-centered psychedelic therapeutics. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2024 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
FAQ
Who is Mary-Elizabeth Gifford and what role did she accept at Clearmind Medicine (CMND) on Oct 27, 2025?
How many patents does Clearmind Medicine (CMND) say it holds as of Oct 27, 2025?
Which clinical sites are running Clearmind Medicine (CMND) trials mentioned in the Oct 27, 2025 announcement?
What experience does Mary-Elizabeth Gifford bring to her Clearmind (CMND) role that relates to policy and advocacy?
Will Mary-Elizabeth Gifford's role at Clearmind (CMND) involve work in Washington, D.C. and New York?
